Compass Therapeutics, Inc.
NASDAQ:CMPX · NASDAQ Capital Market
-$0.03 today
Vol 9.27M · Avg 7.64M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-33.8%
avg -22.7%
ROIC
-35.3%
avg -55.2%
ROA
-30.3%
avg -49.5%
Analysis
ROA is currently the strongest return metric at -30.3% versus its period average of -49.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas J. Schuetz | Chief Executive Officer & Vice Chairman | $1.03M | — | 65 | $6.60M | 4.78% |
Barry Shin | Chief Financial Officer | $717,000.00 | — | 54 | $670,000.00 | 0.48% |
Jonathan Anderman | Senior Vice President, General Counsel & Corporate Secretary | $648,000.00 | — | 43 | $196,000.00 | 0.14% |
Bing Gong | Chief Scientific Officer | $445,500.00 | — | 50 | — | — |
Cynthia A. Sirard | Chief Medical Officer | — | — | 56 | $0.00 | <0.01% |
James Kranz | Vice President and Head of Chemistry Manufacturing & Controls | — | — | — | $90,000.00 | 0.07% |
Arjun Prasad | Chief Commercial Officer | — | — | 48 | $0.00 | <0.01% |
Anna Gifford | Senior Manager of Communications & Chief of Staff | — | — | — | — | — |
Neil L. Lerner | Senior Vice President & Chief Accounting Officer | — | — | 59 | $397,500.00 | 0.29% |
Karin Herrera | Senior Vice President & Head of Clinical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$75,600.00
Sells
0
$0.00
Net Sentiment
+$75,600.00
Net buying
Most Active
Lerner Neil
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Lerner Neil Direct | Buy | 15.0K | $1.89 | $28,350.00 | |
| Apr 29, 2026 | Anderman Jonathan Direct | Buy | 25.0K | $1.89 | $47,250.00 |
Analysis
Insiders reported 2 buys worth $75,600.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $75,600.00. Lerner Neil was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$992.24M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$890.35M
Omeros Corporation
NASDAQ:OMER
$746.91M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$501.06M
Monopar Therapeutics Inc.
NASDAQ:MNPR
$441.27M
Ocugen, Inc.
NASDAQ:OCGN
$423.15M
Bicycle Therapeutics plc
NASDAQ:BCYC
$276.54M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$194.80M
Gossamer Bio, Inc.
GOSS
$39.45M
Who manages CMPX?
Compass Therapeutics, Inc. (CMPX) lists 10 active executives. The top listed executive is Cynthia A. Sirard, Chief Medical Officer.
Are CMPX insiders buying or selling?
Recent insider activity shows net buying of $139.34M.
Explore More
Continue the stock analysis
Jump to another research area for this company.